Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2014

View Archived Issues

Regulus Therapeutics nominates RG-012 as candidate for Alport syndrome

A novel screening approach to identify disease-associated candidate genes

New trials evaluate CardioCell's itMSC therapy for acute myocardial infarction

Vitae Pharmaceuticals earns milestone payment from Boehringer Ingelheim

Cempra begins phase I trial of solithromycin in a pediatric population

Raptor Pharmaceutical reports results for RP-103 in Huntington's disease

Invion and 3M Drug Delivery Systems collaborate on inhaled respiratory drugs

FDA accepts Merck & Co.'s BLA for V-503 for review

Anoro receives positive CHMP opinion for the treatment of COPD

MolecularMD to develop diagnostic test to support CML treatment-free remission trials

TrpV4 inhibition shows promise as a treatment approach for acute ischemic stroke

Bristol-Myers Squibb designs new P2Y1 receptor antagonists

Amgen presents new protein kinase pim inhibitors for cancer

OncoMed Pharmaceuticals begins third phase Ib trial of OMP-54F28

Novel agents for thromboembolic disorders patented by Bristol-Myers Squibb

FDA grants fast track designation to Egalet-001 and Egalet-002

U.S. and Chinese group prepares new agents for cancer and other disorders

Japan's MHLW expands approval of Hisamitsu's estradiol transdermal patch

Kyowa Hakko Kirin obtains additional approval for Regpara tablets in Japan

T1128C NPY polymorphism identified as a stroke risk factor

Scientists at Merck & Co. divulge novel GPR40 agonists for diabetes

Purdue Pharma and Shionogi & Co. patent new NOP receptor ligands

Patient enrollment is ongoing in a phase II study of GSK-249320

EMA committee recommends approval of BioMarin's Vimizim for Morquio A syndrome

Lucentis approved in Japan for diabetic macular edema

GSK's umeclidinium recommended for E.U. approval in treatment of COPD

AB Science reports initiation of new phase III study of masitinib plus docetaxel in prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...